Successful digital diabetes platform vendors, like Glooko, are aware of the needs of healthcare providers and offer advanced population management solutions that provide ongoing patient tracking, real-time dashboards and the ability to detect high-risk patients.

In an era of health fads and medical disinformation, building a business on evidence-led, authoritative information is more important than ever. Glooko is a great example of doing this well.

Diabetes technology and data sharing capabilities have come an incredibly long way, and Glooko has helped lead the way. This retrospective explores Glooko’s historic milestones.

Glooko Chief Medical Officer Mark Clements, M.D., Ph.D. discusses why remote patient monitoring and other at-home digital health innovations are becoming part of the standard of care for diabetes and other chronic diseases.

Glooko CEO Russ Johannesson discusses the different interpretations of telehealth, the rapid development and adoption of telehealth during COVID-19 and his predictions for how innovative technologies will be leveraged moving forward.

Terumo and Glooko announced a collaboration to integrate their technologies and create new diabetes data sharing solutions.

Glooko CEO Russ Johannesson discusses the company’s connected diabetes care strategy, including its recent agreement with Johns Hopkins HealthCare Solutions and acquisition of DIABNEXT.

L’équipe de la MedTech rejoint l’équipe de Glooko au sein du bureau parisien de la société et les deux plateformes sont désormais commercialisées sur le marché français. L’Américain ambitionne ainsi de développer sa communauté d’utilisateurs.

In its second acquisition of 2022 so far, Glooko is forging ahead in its mission not only to bulk up its digital diabetes management offerings but also to expand their reach around the world.

L’entreprise basée à Paris propose une plateforme de télésurveillance du diabète qui améliore la collaboration patient-praticien.